543943
Asarfi Hospital financials
- Market cap
- ₹378 Cr
- Sector
- Healthcare
- Calls analysed
- 3
Asarfi Hospital Q4 FY26
What went well
- FY26 consolidated revenue from operations increased by 42% YoY to INR 173.5 crores, up from INR 121 crores in FY25.
- FY26 consolidated PAT grew by 58% YoY to INR 16.7 crores, with PAT margin improving to 10%.
- Q4 FY26 consolidated revenue grew by 29% YoY to INR 45.2 crores.
What to watch
- Delay in operationalizing the bone marrow transplant unit due to procedural delays in organ transplant policy approval.
- Proposed merger with another hospital is delayed due to shareholder inheritance issues.
What Asarfi Hospital does
Asarfi Hospital Limited operates two hospitals in the Dhanbad region of Jharkhand: a Super-Specialty Hospital offering cardiology, neurosciences, general medicine, orthopaedics, obstetrics & gynaecology, general surgery and other specialties with ICU/NICU/SICU, CCU, emergency and a cardiac unit; and the Asarfi Cancer Institute, a dedicated comprehensive cancer-care hospital offering medical, surgical and radiation oncology with day-care chemotherapy. It earns revenue from in-patient (IPD) and out-patient (OPD) treatment, diagnostics and surgeries, and is empanelled with government schemes (Govt of Jharkhand's MGBUY, East Central Railway, Coal India Limited) and TPAs for cashless healthcare.
Segments
- Super-Specialty Hospital
- Cancer Hospital (Asarfi Cancer Institute)
- Hospital units
- 2 (Super-Specialty Hospital + Asarfi Cancer Institute), Dhanbad, Jharkhand
- Total bed capacity
- 350 (297 effective beds)
- Super-Specialty Hospital beds
- 285
- Cancer Hospital beds
- 65
- Doctors
- 66 full-time + 15+ visiting (80+ total)
- Nursing & support staff
- 500
Guidance record · Q4 FY26
what the last two calls moved 13 tracked 1 delivered 3 missed 9 open- Total Revenue delivered said Q2 FY26 Promised: Rs. 160 crores for FY26 Q4 FY26: Achieved. FY26 consolidated revenue was INR 173.5 crores, exceeding the target.
- Cancer Hospital ARPOB went quiet said Q4 FY25 Promised: Rs. 45,000 Q4 FY26: This specific metric was not mentioned in the Q4 FY26 call. Only a blended ARPOB of Rs. 23,000 was provided.
- Total Bed Capacity delayed said Q4 FY25 Promised: 500 beds by FY27 Q4 FY26: Timeline pushed. New target is '500 plus beds' as part of 'Vision 2028 roadmap'.
All 13 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 32.8%, net profit up 33.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 31 | 33 | 35 | 36 | 45 +45% | 46 +40% | 45 +28% | 47 +33% |
| EBITDA | 7 | 7 | 6 | 7 | 9 +31% | 10 +45% | 8 +22% | 9 +34% |
| Net profit | 3 | 3 | 4 | 3 | 4 +48% | 5 +101% | 4 +7% | 4 +33% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +27.2% 1Y
1Y: ₹150.2 on 10 Sept 2025 → ₹191. High ₹252.8 (8 May 2026), low ₹125.5 (10 Oct 2025).
How the price took the results
close before → close after
- Q4 FY26
- +1.8%
- 27 May
- Q2 FY26
- +4.4%
- 19 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 40.9% a year over 1 year, FY25 to FY26. Operating margin narrowed to 19.8%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹122 Cr | ₹172 Cr |
| Operating profit | ₹25 Cr | ₹34 Cr |
| Operating margin | 20.5% | 19.8% |
| Interest | ₹4 Cr | ₹4 Cr |
| Depreciation | ₹13 Cr | ₹11 Cr |
| Net profit | ₹11 Cr | ₹17 Cr |
| Net margin | 9.0% | 9.9% |
| Cash from operations | ₹-4 Cr | ₹19 Cr |
| Free cash flow | ₹-14 Cr | ₹1 Cr |
| ROCE | 16.0% | 19.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹1 Cr | ₹1 Cr | ₹14 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr |
| Reserves | ₹16 Cr | ₹21 Cr | ₹27 Cr | ₹51 Cr | ₹62 Cr | ₹79 Cr |
| Borrowings | ₹7 Cr | ₹12 Cr | ₹17 Cr | ₹32 Cr | ₹49 Cr | ₹58 Cr |
| Other liabilities | ₹13 Cr | ₹28 Cr | ₹34 Cr | ₹52 Cr | ₹34 Cr | ₹38 Cr |
| Total liabilities | ₹37 Cr | ₹63 Cr | ₹93 Cr | ₹154 Cr | ₹164 Cr | ₹194 Cr |
| Fixed assets | ₹22 Cr | ₹31 Cr | ₹39 Cr | ₹94 Cr | ₹101 Cr | ₹108 Cr |
| Capital work in progress | ₹2 Cr | ₹9 Cr | ₹18 Cr | ₹0 Cr | ₹2 Cr | ₹2 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹13 Cr | ₹22 Cr | ₹37 Cr | ₹60 Cr | ₹61 Cr | ₹84 Cr |
| Total assets | ₹37 Cr | ₹63 Cr | ₹93 Cr | ₹154 Cr | ₹164 Cr | ₹194 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public added +0.32 pp while DIIs trimmed −0.22 pp. The shareholder count grew 19% to 1,399.
- Promoters
- 61.2%
- DIIs
- 3.0%
- Public
- 35.9%
Since Jun 2025
- Public +0.32 pp
- DIIs −0.22 pp
- FIIs −0.10 pp
How it drifted, 9 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 61.2%, DIIs 3.3%, Public 35.6%.Mar '24: Promoters 61.2%, DIIs 2.3%, Public 36.5%.Sep '24: Promoters 61.2%, DIIs 1.9%, Public 36.9%.Mar '25: Promoters 61.2%, DIIs 2.9%, Public 35.9%.Jun '25: Promoters 61.2%, FIIs 0.1%, DIIs 3.2%, Public 35.5%.Sep '25: Promoters 61.2%, FIIs 0.1%, DIIs 2.2%, Public 36.6%.Dec '25: Promoters 61.2%, DIIs 2.0%, Public 36.9%.Mar '26: Promoters 61.2%, DIIs 2.4%, Public 36.4%.Jun '26: Promoters 61.2%, DIIs 3.0%, Public 35.9%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Asarfi Hospital above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Harendra Singh | 18.78% | unchanged |
| Nayan Prakash Singh | 17.74% | unchanged |
| Udai Pratap Singh | 11.96% | unchanged |
| Madhuri Singh | 4.02% | unchanged |
| Asap Impact Private Limited | 3.33% | unchanged |
| Nitu Singh | 2.89% | unchanged |
| Gopal Singh | 2.40% | unchanged |
| Sukanti Kumar Das | 1.68% | unchanged |
| Rajiv Ranjan Singh | 1.19% | unchanged |
| Saroj Singh | 1.03% | unchanged |
| Indu Jain | 1.02% | unchanged |
| Ritesh Kumar Singh | 0.35% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
All earnings calls (3)
Read the Q4 FY26 call →Learn to analyse Asarfi Hospital
Guides on how to read this kind of business and the numbers that matter.